The clearance brings an oral form of Novoâs Wegovy to market ahead of Lillyâs rival medication and kicks off the next phase ...
The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.
The startupâs filing comes during a broader biotech recovery thatâs made some industry watchers optimistic IPOs could rebound ...
Two pilot programs would tie Medicare costs and rebates in the U.S. to whatâs paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an âoff the shelfâ cell therapy showed promise ...
The clearance is the first in Cytokineticsâ lengthy history and pits its drug Myqorzo against Bristol Myersâ Camzyos, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback